#USA #New York #Pomerantz LLP #SEC Investigation #Valneva SE

Pomerantz Law Firm Investigates Valneva SE: Important Notice to Investors

On April 9, 2026, the Pomerantz Law Firm announced that it is investigating claims on behalf of shareholders of Valneva SE (NASDAQ: VALN). This investigation arises in the wake of troubling news regarding Valneva's vaccine candidate, which has raised serious concerns among investors. If you have experienced losses in Valneva’s stock and have valuable information regarding these events, the firm is urging you to step forward.

Background on Valneva SE

Valneva SE, a biotechnology company specializing in developing vaccines, has been in the spotlight following the recent announcement with its partner Pfizer Inc. On March 23, 2026, Valneva released topline results from its Phase 3 VALOR trial for its Lyme disease vaccine. While the companies presented the data as positive, they also disclosed that the vaccine did not meet its primary endpoint due to a low incidence of disease cases.

This news had a dramatic impact on Valneva’s American Depositary Receipt (ADR) prices, which plummeted by 37.11%, falling from $10.32 to $6.49 on the same day. This sharp decline has left many investors questioning the company's communication and overall business practices, sparking the investigation by Pomerantz LLP.

The Investigation

Pomerantz LLP is examining whether Valneva and its executives engaged in any form of securities fraud or other unlawful business practices that may have misled investors. The firm is recognized for its expertise in securities class actions, backed by over 85 years of experience in fighting for the rights of investors against fraudulent companies. Investor confidence is paramount, and any indications of misconduct can severely damage a company's reputation and financial standing.

What Investors Should Know

Affected investors are encouraged to reach out to Danielle Peyton at Pomerantz LLP, as the firm is looking to gauge the impact of the trial's results on the stock and explore potential legal actions. For those wishing to participate in the class action lawsuit, details can be found on their website.

As the investigation unfolds, it emphasizes the importance of transparency in corporate communications, particularly when it concerns clinical trials and the results shared with the public and investors alike. If you have held Valneva shares during this turbulent period and believe you may have been misled, now is the time to consider your options.

Conclusion

The potential implications of this investigation could be significant, not only for Valneva SE but also for all its investors. This situation serves as a reminder of the potential risks within the biotech industry and the critical importance of due diligence. For ongoing updates and more detailed legal insights, interested parties can visit Pomerantz's website.

For any inquiries, please contact Danielle Peyton of Pomerantz LLP at [email protected] or by phone at 646-581-9980, ext. 7980. Your rights as an investor matter, and you may have valuable information that could assist in holding corporate leaders accountable for their actions.